A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium
Latest Information Update: 28 Apr 2026
At a glance
- Drugs Nintedanib (Primary)
- Indications Pterygium
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cloudbreak Pharma
Most Recent Events
- 22 Apr 2026 According to Cludbreak media release, the data from the trial will be presented at Eyecelerator (partnership between ASCRS (American Society of Cataract and Refractive Surgery) and the American Academy of Ophthalmology) at the ARVO 2026.
- 01 Sep 2018 Status changed from active, no longer recruiting to completed.
- 17 Jul 2018 Planned primary completion date changed from 26 May 2018 to 30 Sep 2018.